Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial

Summary

This Phase I clinical trial is designed to evaluate the safety, tolerability of XS228 ( iPSC-Derived Motor Neuron Progenitor Cells) in patients with Subacute Spinal Cord Injury

Timeline

Start

2025-07-02

Primary completion

2028-02-21

Completion

2028-05-30

Publications

• Pang M, Kang J, Yang Y, He T, Yao S, Hu B, Li X, Liu B, Rong L. Safety and early efficacy of iPSC-derived motor neuron progenitor cells in subacute spinal cord injury: protocol for a phase I, multicentre, open-label, single-arm trial. BMJ Open. 2026 Jul 8;16(7):e111718. doi: 10.1136/bmjopen-2025-111718.

Drugs

Indications